See more : NanoTIM Co. Ltd. (417010.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of Myovant Sciences Ltd. (MYOV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Myovant Sciences Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- URA Holdings Plc (URAH.L) Income Statement Analysis – Financial Results
- IDT International Limited (0167.HK) Income Statement Analysis – Financial Results
- Sunac Services Holdings Limited (SSHLY) Income Statement Analysis – Financial Results
- Bearing Lithium Corp. (BRZ.V) Income Statement Analysis – Financial Results
- Rapid Nutrition PLC (ALRPD.PA) Income Statement Analysis – Financial Results
Myovant Sciences Ltd. (MYOV)
About Myovant Sciences Ltd.
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 230.97M | 59.32M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 51.55M | 1.97M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 179.42M | 57.35M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 77.68% | 96.69% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 107.40M | 136.71M | 192.56M | 222.61M | 116.83M | 43.50M |
| General & Administrative | 0.00 | 0.00 | 82.33M | 42.22M | 24.23M | 12.36M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 259.36M | 181.42M | 82.33M | 42.22M | 24.23M | 12.36M |
| Other Expenses | 40.04M | 1.66M | 1.62M | -309.00K | 67.00K | -139.00K |
| Operating Expenses | 366.77M | 318.14M | 274.89M | 264.83M | 141.06M | 55.86M |
| Cost & Expenses | 418.32M | 320.10M | 274.89M | 264.83M | 141.06M | 55.86M |
| Interest Income | 384.00K | 211.00K | 2.55M | 881.00K | 0.00 | 0.00 |
| Interest Expense | 13.97M | 10.40M | 12.66M | 8.82M | 2.05M | 0.00 |
| Depreciation & Amortization | 3.46M | 2.69M | 1.77M | 438.00K | 243.00K | 61.00K |
| EBITDA | -183.89M | -258.09M | -273.80M | -255.88M | -140.75M | 0.00 |
| EBITDA Ratio | -79.62% | -435.11% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -187.35M | -260.78M | -270.71M | -264.83M | -141.06M | -55.86M |
| Operating Income Ratio | -81.11% | -439.64% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -13.59M | 5.99M | -17.51M | -8.25M | -1.98M | -27.66M |
| Income Before Tax | -200.93M | -254.80M | -288.23M | -273.08M | -143.04M | -83.51M |
| Income Before Tax Ratio | -86.99% | -429.55% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 5.05M | 336.00K | 761.00K | 476.00K | 213.00K | -74.00K |
| Net Income | -205.98M | -255.13M | -288.99M | -273.55M | -143.26M | -83.44M |
| Net Income Ratio | -89.18% | -430.12% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.22 | -2.83 | -3.37 | -4.09 | -2.41 | -1.70 |
| EPS Diluted | -2.22 | -2.83 | -3.37 | -4.09 | -2.41 | -1.70 |
| Weighted Avg Shares Out | 92.97M | 90.04M | 85.84M | 66.91M | 59.52M | 49.18M |
| Weighted Avg Shares Out (Dil) | 92.97M | 90.04M | 85.84M | 66.91M | 59.52M | 49.18M |
Why The Misunderstood Pfizer Deal Makes Myovant A Great Low-Risk Investment
Myovant (MYOV), Pfizer Start Dosing in Relugolix Combo Study
Myovant Sciences Appoints Lauren Merendino as Chief Commercial Officer
Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorization Application for Relugolix for the Treatment of Advanced Prostate Cancer
Myovant's (MYOV) Data on Relugolix for Uterine Fibroids Positive
Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Myovant Sciences to Present at Upcoming Investor Conferences
Sumitovant Biopharma Announces Publication in the New England Journal of Medicine of Myovant Sciences Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
Source: https://incomestatements.info
Category: Stock Reports